Literature DB >> 21889337

Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.

Krupa Shukla1, Ajit G Thomas, Dana V Ferraris, Niyada Hin, Rita Sattler, Jesse Alt, Camilo Rojas, Barbara S Slusher, Takashi Tsukamoto.   

Abstract

A series of sulfasalazine analogs were synthesized and tested for their ability to block cystine-glutamate antiporter system xc⁻ using L-[(14)C]cystine as a substrate. Replacement of sulfasalazine's diazo group with an alkyne group led to an equally potent inhibitor, 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)ethynyl)benzoic acid 6. Our SAR studies also revealed that the carboxylate group of sulfasalazine is essential for its inhibitory activity while the phenolic hydroxyl group is dispensable. Truncated analogs lacking an N-pyridin-2-ylsulfamoyl moiety were less potent than sulfasalazine, but may serve as more tractable templates because of their low molecular weight by applying a variety of fragment growing approaches. Given that sulfasalazine is rapidly metabolized through cleavage of the diazo bond, these analogs may possess a more desirable pharmacological profile as system xc- blockers, in particular, for in vivo studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889337     DOI: 10.1016/j.bmcl.2011.07.081

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  Sulfasalazine for brain cancer fits.

Authors:  Harald Sontheimer; Richard J Bridges
Journal:  Expert Opin Investig Drugs       Date:  2012-03-12       Impact factor: 6.206

2.  SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma.

Authors:  Stephanie M Robert; Susan C Buckingham; Susan L Campbell; Stefanie Robel; Kenneth T Holt; Toyin Ogunrinu-Babarinde; Paula P Warren; David M White; Meredith A Reid; Jenny M Eschbacher; Michael E Berens; Adrienne C Lahti; Louis B Nabors; Harald Sontheimer
Journal:  Sci Transl Med       Date:  2015-05-27       Impact factor: 17.956

3.  Microwave accelerated synthesis of isoxazole hydrazide inhibitors of the system xc- transporter: Initial homology model.

Authors:  Afnan A Matti; Joseph Mirzaei; John Rudolph; Stephen A Smith; Jayme L Newell; Sarjubhai A Patel; Michael R Braden; Richard J Bridges; Nicholas R Natale
Journal:  Bioorg Med Chem Lett       Date:  2013-08-27       Impact factor: 2.823

Review 4.  Heteromeric Amino Acid Transporters in Brain: from Physiology to Pathology.

Authors:  Ekaitz Errasti-Murugarren; Manuel Palacín
Journal:  Neurochem Res       Date:  2021-02-19       Impact factor: 3.996

5.  MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.

Authors:  Yuxiong Lu; Qing Yang; Yubin Su; Yin Ji; Guobang Li; Xianzhi Yang; Liyan Xu; Zhaoliang Lu; Jiajun Dong; Yi Wu; Jin-Xin Bei; Chaoyun Pan; Xiaoqiong Gu; Bo Li
Journal:  Cell Death Dis       Date:  2021-05-19       Impact factor: 8.469

6.  Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.

Authors:  Scott J Dixon; Darpan N Patel; Matthew Welsch; Rachid Skouta; Eric D Lee; Miki Hayano; Ajit G Thomas; Caroline E Gleason; Nicholas P Tatonetti; Barbara S Slusher; Brent R Stockwell
Journal:  Elife       Date:  2014-05-20       Impact factor: 8.140

Review 7.  Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Authors:  William M Johnson; Amy L Wilson-Delfosse; John J Mieyal
Journal:  Nutrients       Date:  2012-10-09       Impact factor: 5.717

8.  High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.

Authors:  Ajit G Thomas; Rita Sattler; Karen Tendyke; Kara A Loiacono; Hans Hansen; Vishal Sahni; Yutaka Hashizume; Camilo Rojas; Barbara S Slusher
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

9.  The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Authors:  Lauren M Slosky; Neemah M BassiriRad; Ashley M Symons; Michelle Thompson; Timothy Doyle; Brittany L Forte; William D Staatz; Lynn Bui; William L Neumann; Patrick W Mantyh; Daniela Salvemini; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Pain       Date:  2016-11       Impact factor: 7.926

10.  The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells.

Authors:  Mami Sato; Ryosuke Kusumi; Shinji Hamashima; Sho Kobayashi; Satoru Sasaki; Yuhei Komiyama; Takuji Izumikawa; Marcus Conrad; Shiro Bannai; Hideyo Sato
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.